Package Insert: Information for the Patient
Rabidux 2.5 mg/1.25 mg Hard Capsules
Rabidux 2.5 mg/2.5 mg Hard Capsules
Rabidux 5 mg/2.5 mg Hard Capsules
Rabidux 5 mg/5 mg Hard Capsules
Rabidux 10 mg/5 mg Hard Capsules
Rabidux 10 mg/10 mg Hard Capsules
ramipril/bisoprolol fumarate
Read this package insert carefully before starting to take this medicine, as it contains important information for you.
Rabidux contains two active principles, bisoprolol fumarate and ramipril in a single capsule:
This medication is used to treat high blood pressure (hypertension) and/or chronic heart failure with left ventricular dysfunction (a disease in which the heart cannot pump enough blood to meet the body's needs, causing dyspnea (difficulty breathing)and edema) and/or to reduce the risk of cardiac events, such as myocardial infarction, in patients with chronic coronary artery disease (a disease in which blood flow to the heart is reduced or blocked) who have already experienced a myocardial infarction and/or undergone a procedure to improve blood flow to the heart by dilating the vessels that irrigate it, or diabetes with at least one cardiovascular risk factor
Instead of taking bisoprolol fumarate and ramipril in separate capsules, you will take a single capsule of this medication that contains both active principles in the same presentation.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication if you:
Your doctor may monitor your kidney function, blood pressure, and electrolyte levels in the blood (such as potassium) at regular intervals. See also the information under the heading "Do not take Rabidux".
Do not stop taking this medication suddenly, as this can cause a severe worsening of the heart condition. Treatment should not be stopped abruptly, especially in patients with coronary artery disease.
Inform your doctor if you think you are (or may be) pregnant. This medication is not recommended at the beginning of pregnancy and should not be taken if you are more than 3 months pregnant, as it can cause serious harm to your baby if taken after the third month of pregnancy (see section "Pregnancy and breastfeeding").
Children and adolescents
This medication is not recommended for use in children and adolescents under 18 years of age.
Other medications and Rabidux
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
There are some medications that can change the effect of this medication or its effect may be changed by this medication. This type of interaction could make one or both medications less effective. It could also increase the risk or severity of side effects.
Make sure to inform your doctor if you are taking any of the following medications:
Taking Rabidux with food, drinks, and alcohol
It is best to take this medication before a meal.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
You should inform your doctor if you think you are (or may be) pregnant. Your doctor will usually recommend that you stop taking this medication before becoming pregnant or as soon as you know you are pregnant and recommend that you take another medication instead of this medication. This medication is not recommended at the beginning of pregnancy and should not be taken if you are more than 3 months pregnant, as it can cause serious harm to your baby if taken after the third month of pregnancy.
Breastfeeding
Inform your doctor if you are breastfeeding or are about to start breastfeeding. This medication is not recommended for breastfeeding mothers, and your doctor may choose another treatment for you if you want to breastfeed, especially if your baby is a newborn or premature.
Driving and operating machines
This medication usually does not affect alertness, but some patients may experience dizziness or weakness due to low blood pressure, particularly at the beginning of treatment or when changing medications, as well as with alcohol. If this occurs, do not drive or operate tools or machines.
Rabidux contains lactose
Rabidux 2.5 mg/1.25 mg contains 40.97 mg of lactose (20.49 mg of glucose and 20.49 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux 2.5 mg/2.5 mg contains 40.97 mg of lactose (20.49 mg of glucose and 20.49 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux 5 mg/2.5 mg contains 81.94 mg of lactose (40.97 mg of glucose and 40.97 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux 5 mg/5 mg contains 81.94 mg of lactose (40.97 mg of glucose and 40.97 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux 10 mg/5 mg contains 163.88 mg of lactose (81.94 mg of glucose and 81.94 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux 10 mg/10 mg contains 163.88 mg of lactose (81.94 mg of glucose and 81.94 mg of galactose) per dose, which should be taken into account in patients with diabetes mellitus.
Rabidux contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per capsule; that is, it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is one capsule once a day. Swallow your capsule with a glass of water in the morning before a meal.
Patients with renal insufficiency
Your doctor will adjust the dose of this medication if you have moderate renal disease. This medication is not recommended if you have severe renal disease.
Patients with hepatic insufficiency
Your doctor will closely monitor the start of treatment with this medication if you have mild or moderate liver disease.
Use in children and adolescents
This medication is not recommended for use in children and adolescents.
If you take more Rabidux than you should
If you take more capsules than prescribed, contact your doctor or pharmacist immediately.
The most likely effect in case of overdose is low blood pressure that may make you feel dizzy or faint (if this happens, lying down with your legs elevated may help), severe difficulty breathing, tremors (due to decreased blood sugar) and slow heart rate.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Rabidux
It is essential to take your medication every day since regular treatment works better. However, if you forget to take a dose of this medication, take the next dose at the usual time. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Rabidux
Do not stop taking this medication suddenly or change the dose without consulting your doctor, as this may cause a severe worsening of heart disease. Treatment should not be abruptly discontinued, especially in patients with coronary artery disease.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking this medicine and consult a doctor immediately if you notice any of the following serious side effects:
This medicine is usually well tolerated, but like any medicine, people may experience different side effects, especially when starting treatment for the first time.
If you notice any of the side effects listed below or not mentioned, inform your doctor or pharmacist immediately:
Very frequent (may affect more than 1 in 10 people):
Frequent (may affect up to 1 in 10 people):
Infrequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
-nightmares, hallucinations,
Very rare (may affect up to 1 in 10,000 people):
Frequency unknown (frequency cannot be estimated from available data):
Concentrated urine (dark-colored), feeling or being sick, muscle cramps, confusion, and attacks that may be due to inadequate secretion of ADH (antidiuretic hormone) can occur with ACE inhibitors. If you have these symptoms, contact your doctor as soon as possible.
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the outer packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 86°F (30°C). Do not refrigerate or freeze.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection pointat the pharmacy. Ask your pharmacist how to dispose of the packaging and unused medications. This will help protect the environment.
Composition of Rabidux
Content of the capsule: lactose monohydrate, poly (vinyl alcohol), sodium croscarmellose (E468), stearate of fumaric acid and sodium, microcrystalline cellulose, anhydrous calcium phosphate, crospovidone type A, anhydrous colloidal silica, and magnesium stearate.
Coating with film:AquaPolish P yellow: hypromellose (E464), hydroxypropylcellulose (E463), medium-chain triglycerides, talc (E553b), titanium dioxide (E171), and yellow iron oxide (E172).
Capsule coating: titanium dioxide (E171), gelatin, red iron oxide (E172) in 5 mg/2.5 mg, 5 mg/5 mg, 10 mg/5 mg, and 10 mg/10 mg capsules, yellow iron oxide (E172) in 2.5 mg/1.25 mg, 2.5 mg/2.5 mg, 5 mg/2.5 mg, 5 mg/5 mg, and 10 mg/5 mg capsules, and quinoline yellow (E104) in 2.5 mg/1.25 mg, 2.5 mg/2.5 mg, and 5 mg/2.5 mg capsules.
Printing ink: shellac (E904), black iron oxide (E172), propylene glycol, strong ammonia solution, and potassium hydroxide.
Appearance of the product and contents of the package
Rabidux 2.5 mg/1.25 mg hard capsules: the capsule has a yellow-colored cap with black printing "2.5 mg" and a white-colored body with black printing "1.25 mg". Contents of the capsule of 2.5 mg/1.25 mg: ramipril powder white or almost white and a yellow-colored, round, biconvex tablet of bisoprolol fumarate.
Rabidux 2.5 mg/2.5 mg hard capsules: the capsule has a yellow-colored cap with black printing "2.5 mg" and a yellow-colored body with black printing "2.5 mg". Contents of the capsule of 2.5 mg/2.5 mg: ramipril powder white or almost white and a yellow-colored, round, biconvex tablet of bisoprolol fumarate.
Rabidux 5 mg/2.5 mg hard capsules: the capsule has an orange-colored cap with black printing "5 mg" and a yellow-colored body with black printing "2.5 mg".
Contents of the capsule of 5 mg/2.5 mg: ramipril powder white or almost white and a yellow-colored, round, biconvex tablet of bisoprolol fumarate.
Rabidux 5 mg/5 mg hard capsules: the capsule has an orange-colored cap with black printing "5 mg" and an orange-colored body with black printing "5 mg".
Contents of the capsule of 5 mg/5 mg: ramipril powder white or almost white and a yellow-colored, round, biconvex tablet of bisoprolol fumarate.
Rabidux 10 mg/5 mg hard capsules: the capsule has a reddish-brown-colored cap with black printing "10 mg" and an orange-colored body with black printing "5 mg". Contents of the capsule of 10 mg/5 mg: ramipril powder white or almost white and a yellow-colored, round, biconvex tablet of bisoprolol fumarate.
Rabidux 10 mg/10 mg hard capsules: the capsule has a reddish-brown-colored cap with black printing "10 mg" and a reddish-brown-colored body with black printing "10 mg".
Contents of the capsule of 10 mg/10 mg: ramipril powder white or almost white and two yellow-colored, round, biconvex tablets of bisoprolol fumarate.
Blister packs of BOPA/Al/PVC-Aluminum.
The capsules are available in boxes of 10, 30, 60, and 100 capsules.
Only some package sizes may be marketed.
Marketing authorization holder
Adamed Laboratorios, S.L.U.
c/ de las Rosas de Aravaca, 31 - 2nd floor
28023 Madrid
Spain
Responsible for manufacturing
ul. Marszalka Józefa Pilsudskiego 5
95-200 Pabianice
Poland
This medicinal product is authorized inthe member states of the European Economic Area with the following names:
Member state | Medicinal product name |
Poland | Ramizek Plus |
Germany | Rabidux2.5 mg/1.25 mg Hard capsules Rabidux2.5 mg/2.5 mg Hard capsules Rabidux5 mg/2.5 mg Hard capsules Rabidux5 mg/5 mg Hard capsules Rabidux 10mg/5 mg Hard capsules Rabidux 10mg/10 mg Hard capsules |
Italy | Rabisop |
Spain | Rabidux 2.5 mg/1.25 mg hard capsules Rabidux 2.5 mg/2.5 mg hard capsules Rabidux 5 mg/2.5 mg hard capsules Rabidux 5 mg/5 mg hard capsules Rabidux 10 mg/5 mg hard capsules Rabidux 10 mg/10 mg hard capsules |
Last revision date of this leaflet: May 2023
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.